" class="no-js "lang="en-US"> Strata Oncology Announces Expansion of Clinical Collaboration with Pfizer for Strata PATH Trial into Early-Stage Cancer - Medtech Alert
Friday, April 12, 2024

Strata Oncology Announces Expansion of Clinical Collaboration with Pfizer for Strata PATH Trial into Early-Stage Cancer

Strata Oncology, Inc. a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced expansion of its clinical collaboration with Pfizer ( NYSE: PFE) in the Strata Precision Indications for Approved THerapies (Strata PATHTM) trial. Strata PATH is a prospective pan-tumor therapeutic trial designed to evaluate the efficacy and safety of multiple FDA-approved cancer therapies in new, biomarker-guided patient populations. Pfizer will provide Braftovi® (encorafenib), Mektovi® (binimetinib), and Lorbrena® (lorlatinib) for up to six new cohorts of patients with early-stage lung, melanoma, colorectal, and other cancers who have evidence of micrometastatic disease after initial treatment. Pfizer is already providing Strata with Braftovi® (encorafenib), Mektovi® (binimetinib), Lorbrena® (lorlatinib), Talzenna® (talazoparib), and Inlyta (axitinib) for evaluation in four late-stage cohorts of the Strata PATH trial.

“The new cohorts of Strata PATH, supported by Pfizer, afford us a very exciting opportunity to move the advances we’ve seen in late-stage cancer into earlier stages of the disease,” said Dan Rhodes, Ph.D., co-founder and Chief Executive Officer, Strata Oncology. “Our goal is to deliver smarter and earlier treatment to every patient and having the support of Pfizer is a testament to the potential of the clinical trials that we are using to accelerate the impact of precision oncology.”

Many of the patients for the new micrometastatic cohorts of Strata PATH will be identified through the Strata SentinelTM trial, a 100,000-patient, prospective, observational, pan-solid tumor study of Strata Oncology’s highly sensitive, tumor-informed circulating tumor DNA (ctDNA)-based MRD test. An advanced molecular therapy selection profile is created simultaneously for every patient assessed with the MRD test. This enables rapid identification of clinical trial opportunities, including Strata PATH, for patients who are positive for ctDNA.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more